EpimAb Biotherapeutics has submitted a listing application to the Hong Kong Stock Exchange (HKEX). Founded in 2015, the clinical-stage biotech focuses on developing T-cell engagers (TCEs) for the treatment of cancer and autoimmune diseases. Its pipeline includes eight internally discovered assets, with its core product EMB-01 being an EGFR×cMET bispecific antibody (BsAb) in Phase II development for metastatic colorectal cancer (mCRC). The company has established multiple global out-licensing deals worth over USD 2.1 billion, ranking it second globally in TCE collaborations by value.

Prior to the IPO filing, the company completed several funding rounds, with a post-money valuation approaching USD 500 million in its most recent financing. Financially, EpimAb reported revenues of zero, RMB 458.9 million, RMB 428.7 million and RMB 91.7 million for 2023, 2024, and the nine months ended 30 September 2024 and 2025 respectively, all derived from licensing and collaboration agreements.

PharmCube's NextBiopharm® database lists seven transactions carried out by EpimAb between 2016 and 2025. Click here to request a free trial for NextBiopharm®.